Stockscreener 앱 받기
69.57
1.09%
0.75
시장 영업 전:
70.47
0.90
+1.29%
전일 마감가:
$68.82
열려 있는:
$68.85
하루 거래량:
652.84K
Relative Volume:
0.55
시가총액:
$7.33B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
55.21
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-0.88%
1개월 성능:
+1.87%
6개월 성능:
+9.78%
1년 성능:
+98.77%
1일 변동 폭
$68.24
$69.65
1주일 범위
$68.24
$71.28
52주 변동 폭
$33.34
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
69.57 | 7.56B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Using economic indicators to assess Corcept Therapeutics Incorporated potentialJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? - MSN
Insider Transactions Reported | Corcept Therapeutics(CORT)saw insider trading activity on 8/26/2025 - AInvest
Price momentum metrics for Corcept Therapeutics Incorporated explained2025 Market Sentiment & Safe Entry Zone Tips - Newser
Can momentum traders help lift Corcept Therapeutics Incorporated2025 Trading Recap & AI Driven Price Predictions - Newser
Using RSI to spot recovery in Corcept Therapeutics IncorporatedWeekly Trend Report & Low Drawdown Momentum Ideas - Newser
Is Corcept Therapeutics Incorporated meeting your algorithmic filter criteriaPortfolio Risk Summary & High Win Rate Trade Tips - Newser
JMEE Analysts Predict 11% Upside for Holdings - AInvest
Published on: 2025-08-25 05:47:25 - Newser
What Technical Tools Say About Corcept Therapeutics Incorporated Recovery2025 Breakouts & Breakdowns & Real-Time Volume Triggers - Newser
Corcept Therapeutics Incorporated’s volatility index tracking explainedTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
Has Corcept Therapeutics Incorporated found a price floorJobs Report & Free Technical Pattern Based Buy Signals - Newser
How to track smart money flows in Corcept Therapeutics IncorporatedJuly 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Can you recover from losses in Corcept Therapeutics IncorporatedJuly 2025 Update & Breakout Confirmation Trade Signals - Newser
Earnings visualization tools for Corcept Therapeutics IncorporatedJuly 2025 Opening Moves & Stock Market Timing Techniques - Newser
Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT - Yahoo Finance
Real time pattern detection on Corcept Therapeutics Incorporated stock2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
When is the best time to exit Corcept Therapeutics IncorporatedTrade Entry Report & Fast Moving Trade Plans - Newser
Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Intraday Action & High Return Trade Guides - classian.co.kr
With 70% Institutional Ownership, Corcept Therapeutics Incorporated (NASDAQ:CORT) Is a Favorite Amongst the Big Guns - 富途牛牛
Regression analysis insights on Corcept Therapeutics Incorporated performanceWeekly Trend Recap & Verified Stock Trade Ideas - Newser
Using data tools to time your Corcept Therapeutics Incorporated exit2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Competitive Positioning of Corcept Therapeutics Incorporated: Is It Leading or LaggingWeekly Volume Report & Technical Pattern Recognition Alerts - Newser
Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant - MSN
Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion - TipRanks
Watch for Bullish Crossover in Corcept Therapeutics IncorporatedJuly 2025 Closing Moves & Consistent Profit Focused Trading Strategies - beatles.ru
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook - Yahoo Finance
5 Must-Read Analyst Questions From Corcept’s Q2 Earnings Call - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,512,452, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics director Swisher sells $159k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics officer sells $2.5M in shares By Investing.com - Investing.com Australia
Corcept therapeutics director Swisher sells $159k in shares - Investing.com
Corcept therapeutics officer sells $2.5M in shares - Investing.com
Corcept Therapeutics Announces CDO William Guyer's Share Buy and Sell Transactions - AInvest
Corcept Therapeutics: Pioneering a $2.8B Market in Type 2 Diabetes via Hypercortisolism Treatment - AInvest
Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT) - Seeking Alpha
Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension - TipRanks
Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study - TipRanks
Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem - Yahoo Finance
Assessing the Impact of Pre-Scheduled Insider Sales at Corcept Therapeutics on Investor Confidence and Market Dynamics - AInvest
Corcept Therapeutics Insider Sold Shares Worth $2,373,237, According to a Recent SEC Filing - MarketScreener
Corcept Therapeutics Insider Sold Shares Worth $393,128, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics officer Lyon sells $393k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock By Investing.com - Investing.com India
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock - Investing.com
Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com
Top chart patterns to watch in Corcept Therapeutics IncorporatedWeekly Trend Recap & Daily Oversold Bounce Ideas - Newser
How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News
How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News
How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News
Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코르셉트 테라퓨틱스 주식 (CORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | Director |
Aug 11 '25 |
Option Exercise |
14.08 |
2,200 |
30,976 |
2,200 |
| Swisher Daniel N JR | Director |
Aug 11 '25 |
Sale |
72.30 |
2,200 |
159,060 |
0 |
| Guyer William | Chief Development Officer |
Aug 08 '25 |
Option Exercise |
21.65 |
35,007 |
757,902 |
40,494 |
| Guyer William | Chief Development Officer |
Aug 08 '25 |
Sale |
71.77 |
35,007 |
2,512,452 |
5,487 |
0.95%
0.90%
자본화:
|
볼륨(24시간):